MX345351B - Compuesto macrociclico y metodos para su produccion. - Google Patents

Compuesto macrociclico y metodos para su produccion.

Info

Publication number
MX345351B
MX345351B MX2013011043A MX2013011043A MX345351B MX 345351 B MX345351 B MX 345351B MX 2013011043 A MX2013011043 A MX 2013011043A MX 2013011043 A MX2013011043 A MX 2013011043A MX 345351 B MX345351 B MX 345351B
Authority
MX
Mexico
Prior art keywords
production
methods
macrocyclic compound
compound
macrocyclic
Prior art date
Application number
MX2013011043A
Other languages
English (en)
Other versions
MX2013011043A (es
Inventor
James Moss Steven
Alan Gregory Matthew
Wilkinson Barrie
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2013011043A publication Critical patent/MX2013011043A/es
Publication of MX345351B publication Critical patent/MX345351B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención proporciona inter alia un compuesto de la fórmula (I) para su uso en el tratamiento de una infección viral o como un inmunosupresor.
MX2013011043A 2011-03-29 2012-03-29 Compuesto macrociclico y metodos para su produccion. MX345351B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production
PCT/GB2012/050700 WO2012131371A1 (en) 2011-03-29 2012-03-29 Macrocyclic compound and methods for its production

Publications (2)

Publication Number Publication Date
MX2013011043A MX2013011043A (es) 2014-04-25
MX345351B true MX345351B (es) 2017-01-26

Family

ID=46001313

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011051A MX345352B (es) 2011-03-29 2012-03-29 Compuestos macrociclicos y metodos para su produccion.
MX2013011043A MX345351B (es) 2011-03-29 2012-03-29 Compuesto macrociclico y metodos para su produccion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013011051A MX345352B (es) 2011-03-29 2012-03-29 Compuestos macrociclicos y metodos para su produccion.

Country Status (29)

Country Link
US (2) US9090657B2 (es)
EP (2) EP2691413B1 (es)
JP (2) JP6118792B2 (es)
KR (2) KR101868084B1 (es)
CN (3) CN103635484B (es)
AR (1) AR085724A1 (es)
AU (2) AU2012235961B2 (es)
BR (2) BR112013024974A2 (es)
CA (2) CA2830831C (es)
CL (2) CL2013002739A1 (es)
CY (2) CY1116318T1 (es)
DK (2) DK2691412T3 (es)
EA (2) EA023848B1 (es)
ES (2) ES2533438T3 (es)
HK (2) HK1189237A1 (es)
HR (2) HRP20150184T1 (es)
IL (2) IL228509B (es)
JO (1) JO3063B1 (es)
MX (2) MX345352B (es)
MY (2) MY170618A (es)
PL (2) PL2691413T3 (es)
PT (2) PT2691413E (es)
RS (2) RS53963B1 (es)
SG (2) SG193568A1 (es)
SI (2) SI2691412T1 (es)
TW (1) TWI525098B (es)
UY (1) UY33993A (es)
WO (2) WO2012131377A1 (es)
ZA (2) ZA201307149B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2533784B1 (en) 2010-02-09 2015-04-22 Neurovive Pharmaceutical AB Sanglifehrin based compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
JP2019535726A (ja) 2016-11-18 2019-12-12 ネウロビベ プハルマセウトイカル エービー サングリフェリンマクロ環状類似体の抗がん化合物としての使用
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
EP1893211B1 (en) 2005-06-17 2011-09-14 Novartis AG Use of sanglifehrin in hcv
CN105056207A (zh) 2007-01-04 2015-11-18 德比奥法姆国际股份有限公司 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
CN102224242B (zh) 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
EP2533784B1 (en) * 2010-02-09 2015-04-22 Neurovive Pharmaceutical AB Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
EP3427737A1 (en) * 2010-12-20 2019-01-16 NeuroVive Pharmaceutical AB Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
CN103635484B (zh) 2017-05-10
CA2830827C (en) 2020-03-10
PT2691413E (pt) 2015-03-25
EP2691412A1 (en) 2014-02-05
JP2014510746A (ja) 2014-05-01
AR085724A1 (es) 2013-10-23
ES2533437T3 (es) 2015-04-10
WO2012131371A1 (en) 2012-10-04
CN103635484A (zh) 2014-03-12
PT2691412E (pt) 2015-03-25
HK1189237A1 (en) 2014-05-30
DK2691413T3 (en) 2015-04-07
MX345352B (es) 2017-01-26
HRP20150184T1 (hr) 2015-05-08
KR101911484B1 (ko) 2018-10-24
JP6118793B2 (ja) 2017-04-26
AU2012235880B2 (en) 2016-11-17
EA023848B1 (ru) 2016-07-29
EP2691413B1 (en) 2014-12-24
KR20140057481A (ko) 2014-05-13
SI2691413T1 (sl) 2015-05-29
ZA201307149B (en) 2015-04-29
US9139613B2 (en) 2015-09-22
JP6118792B2 (ja) 2017-04-26
CL2013002740A1 (es) 2014-07-11
AU2012235880A1 (en) 2013-10-17
CA2830831A1 (en) 2012-10-04
CN103619869A (zh) 2014-03-05
IL228508B (en) 2018-01-31
DK2691412T3 (en) 2015-04-07
HK1189236A1 (en) 2014-05-30
SI2691412T1 (sl) 2015-05-29
JO3063B1 (ar) 2017-03-15
CY1116318T1 (el) 2017-02-08
US20120251581A1 (en) 2012-10-04
EA201391399A1 (ru) 2014-02-28
BR112013024974A2 (pt) 2016-09-06
CY1116186T1 (el) 2017-02-08
AU2012235961A1 (en) 2013-10-10
PL2691413T3 (pl) 2015-05-29
IL228508A0 (en) 2013-12-31
ES2533438T3 (es) 2015-04-10
TWI525098B (zh) 2016-03-11
IL228509B (en) 2018-02-28
ZA201307231B (en) 2015-05-27
IL228509A0 (en) 2013-12-31
PL2691412T3 (pl) 2015-08-31
RS53963B1 (en) 2015-08-31
EP2691413A1 (en) 2014-02-05
SG193569A1 (en) 2013-11-29
RS53964B1 (en) 2015-08-31
CL2013002739A1 (es) 2014-07-11
JP2014514290A (ja) 2014-06-19
MY170637A (en) 2019-08-21
CN107417766A (zh) 2017-12-01
KR20140071958A (ko) 2014-06-12
EA201391396A1 (ru) 2014-02-28
EA023907B1 (ru) 2016-07-29
SG193568A1 (en) 2013-11-29
MX2013011051A (es) 2014-03-13
TW201300398A (zh) 2013-01-01
US9090657B2 (en) 2015-07-28
EP2691412B1 (en) 2014-12-24
CN103619869B (zh) 2015-11-25
US20140038885A1 (en) 2014-02-06
WO2012131377A1 (en) 2012-10-04
MX2013011043A (es) 2014-04-25
UY33993A (es) 2012-10-31
CA2830831C (en) 2020-03-10
BR112013024965A2 (pt) 2017-04-18
MY170618A (en) 2019-08-21
KR101868084B1 (ko) 2018-06-18
AU2012235961B2 (en) 2016-09-01
HRP20150187T1 (en) 2015-06-05
CA2830827A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
MX2013011043A (es) Compuestos macrociclico y metodos para su produccion.
MD20140047A2 (ro) Inhibitori ai protein kinazei
IN2014MN02652A (es)
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12014501417A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MY167652A (en) Disposable diaper
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
MX2014006686A (es) Derivaods novedosos de pirrol.
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
GB201107985D0 (en) Process
PH12015500399A1 (en) Azaindolines
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
IN2014DN10658A (es)
MX2013005821A (es) Benzoxazepinas como inhibidores de fosfatidilinositol/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
UA65038U (ru) Способ лечения больных послеродовыми психозами

Legal Events

Date Code Title Description
FG Grant or registration